Skip to Main content Skip to Navigation
Journal articles

Mitoxantrone in the treatment of multiple sclerosis.: Mitoxantrone in the treatment of multiple sclerosis

Abstract : Mitoxantrone is useful for the treatment of cancer and MS and, as with other chemotherapeutic agents, many studies have examined its tolerability. The suitability of mitoxantrone in MS is particularly interesting because of its role in treating various stages of the disease. Evidence shows that mitoxantrone could be a first-line treatment for malignant forms of MS, and a second-line drug in relapsing-remitting or secondary progressive MS that is unresponsive to interferon beta-1a, -1b or glatiramer acetate. Mitoxantrone should, however, be restricted to patients with demonstrable inflammatory disease activity, and should only be prescribed by neurologists with previous experience in both MS and mitoxantrone therapy. This review examines the properties of mitoxantrone, its tolerability, and discusses its suitability for treating various forms of MS, referring to several important studies.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00136481
Contributor : Aurore Quentin <>
Submitted on : Wednesday, March 14, 2007 - 10:29:06 AM
Last modification on : Thursday, March 5, 2020 - 6:38:47 PM

Identifiers

  • HAL Id : inserm-00136481, version 1
  • PUBMED : 16417821

Collections

Citation

Sean Morrissey, Emmanuelle Le Page, Gilles Edan. Mitoxantrone in the treatment of multiple sclerosis.: Mitoxantrone in the treatment of multiple sclerosis. International MS journal / MS Forum, 2005, 12 (3), pp.74-87. ⟨inserm-00136481⟩

Share

Metrics

Record views

105